These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 118141)

  • 1. A new determination method of antiactivator in human plasma.
    Toki N; Hayashi M; Takasugi S
    Hiroshima J Med Sci; 1979 Sep; 28(3):133-9. PubMed ID: 118141
    [No Abstract]   [Full Text] [Related]  

  • 2. [Thromboelastographic method of determination of plasminogen proactivator, antiactivator, and antiplasmin activity].
    Levin GIa
    Lab Delo; 1975; (11):650-1. PubMed ID: 54484
    [No Abstract]   [Full Text] [Related]  

  • 3. Activities of antiplasmin and antiplasminogen activator in serous middle ear effusions.
    Hamaguchi Y; Ohi M; Sakakura Y; Miyoshi Y
    Ann Otol Rhinol Laryngol; 1985; 94(3):293-6. PubMed ID: 3925865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor.
    Korninger C; Collen D
    Thromb Haemost; 1981 Oct; 46(3):662-5. PubMed ID: 6171907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin).
    Du XH; Glas-Greenwalt P; Kant KS; Allen CM; Hayes S; Pollak VE
    Clin Nephrol; 1985 Oct; 24(4):186-91. PubMed ID: 3933871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of fibrinolytic activity of uremic and longterm hemodialytic patients with special reference to fibrinolytic inhibitor.
    Homma T; Ichikawa T
    Biochem Exp Biol; 1979; 15(3):229-36. PubMed ID: 122165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Determination of the antiactivator activity in human and animal blood plasma using tissue plasminogen activator].
    Andreenko GV; Shimonaeva EE
    Vopr Med Khim; 1983; 29(5):112-4. PubMed ID: 6417906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The determination of antiactivator; especially inhibitors against the activator-induced fibrin clot lysis (author's transl)].
    Matsuda M; Yoshida N; Moroi M; Aoki N
    Rinsho Byori; 1976 Apr; 24(4):325-8. PubMed ID: 819683
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular mechanism of fibrinolysis.
    Lijnen HR; Collen D
    Adv Exp Med Biol; 1984; 164():217-28. PubMed ID: 6421102
    [No Abstract]   [Full Text] [Related]  

  • 10. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma.
    Verheijen JH; Chang GT; Kluft C
    Thromb Haemost; 1984 Jul; 51(3):392-5. PubMed ID: 6437006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter-alpha-antiplasmin: its distinction from antiactivator.
    Gallimore MJ
    Thromb Res; 1978 Apr; 12(4):687-92. PubMed ID: 149395
    [No Abstract]   [Full Text] [Related]  

  • 12. Purification and properties of an antiactivator fraction from bovine serum.
    Nanninga LB; Guest MM
    Thromb Haemost; 1979 Oct; 42(3):855-63. PubMed ID: 92070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of hemostasis in ischemic cerebrovascular disease. III. Abnormalities in vascular plasminogen activators, antiactivators and alpha 2-antiplasmin.
    Mettinger KL; Egberg N
    Thromb Res; 1982 May; 26(3):203-10. PubMed ID: 6810498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue plasminogen activator inhibitor in human plasma: development of a functional assay system and demonstration of a correlating Mr = 50,000 antiactivator.
    Korninger C; Wagner O; Binder BR
    J Lab Clin Med; 1985 Jun; 105(6):718-24. PubMed ID: 3923146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma fibrinolytic activity in patients undergoing major abdominal surgery.
    Mellbring G; Dahlgren S; Wiman B
    Acta Chir Scand; 1985; 151(2):109-14. PubMed ID: 3873768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the blood fibrinolytic enzyme system of patients with cutaneous vasculitis.
    Toki N; Yamura T
    Br J Dermatol; 1980 Jul; 103(1):41-50. PubMed ID: 6775670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current developments in fibrinolytic therapy].
    Rijken DC
    Ned Tijdschr Geneeskd; 1985 Sep; 129(37):1768-72. PubMed ID: 3934567
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiactivator in plasma of patients with Behçet's disease.
    Tsushima H; Toki N
    J Dermatol; 1981 Oct; 8(5):379-83. PubMed ID: 6173406
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma coagulation proteases, proteolytic inhibitors, and their interaction with platelets.
    Rao AK; Schmaier AH; Colman RW
    Pathobiol Annu; 1982; 12():35-64. PubMed ID: 6186978
    [No Abstract]   [Full Text] [Related]  

  • 20. A new method for the determination of plasma activators fibrinolysis.
    Margalit R; Gidron E; Shalitin Y
    Thromb Haemost; 1977 Apr; 37(2):210-5. PubMed ID: 577625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.